The challenges of a randomised placebo-controlled trial of CTO PCI vs. placebo with optimal medical therapy: The ORBITA-CTO pilot study design and protocol
Sarosh Khan(Essex Cardiothoracic Centre), John R. Davies(St James's University Hospital), Emmanouil S. Brilakis(Minneapolis Heart Institute Foundation), Shah Mohdnazri(Essex Cardiothoracic Centre), Kare Tang(Essex Cardiothoracic Centre), Christopher Cook(Imperial College London), Rupert Simpson(Essex Cardiothoracic Centre), James Spratt(St George's, University of London), Thomas Keeble(Essex Cardiothoracic Centre), Peter O’Kane(Royal Bournemouth Hospital), Grigoris V. Karamasis(National and Kapodistrian University of Athens), Samer Fawaz(Essex Cardiothoracic Centre), Sean Gallagher(University Hospital of Wales), Rasha Al‐Lamee(Imperial College Healthcare NHS Trust), Paul A. Kelly(Essex Cardiothoracic Centre), C. W. Robertson(University of Strathclyde)
Cited by 11
Related Papers
Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial
|The Lancet|2017|1k
Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest
|New England Journal of Medicine|2021|979
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction
|New England Journal of Medicine|2022|566
Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention
|Circulation|2019|433
Outcomes After Complete Versus Incomplete Revascularization of Patients With Multivessel Coronary Artery Disease
|Journal of the American College of Cardiology|2013|389